Evidence map›Paper›PMID 35524839›Full record

Trial reportAdvances in therapy2022

Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.

Myung-Yong Lee, Sola Han, Oh Young Bang, Young Keun On, Sung-Won Jang, Seongwook Han, Jaeyun Ryu, Yoo-Jung Park, Seongsik Kang, Hae Sun Suh and 1 more

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03572972 (THE REAL WORLD EVIDENCE ON TREATMENT PATTERNS, EFFECTIVENESS, AND SAFETY OF DRUGS FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN KOREA), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03572972 completednot on this map

The real world evidence on treatment patterns, effectiveness, and safety of drugs for stroke prevention in nonvalvular atrial fibrillation patients in korea

TypeobservationalSponsorPfizerRan2018 to 2018Enrolled64,684ConditionsAtrial FibrillationArmsApixaban, Dabigatran, Rivaroxaban, warfarin, Antiplatelets
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. StandardizedFrontiers in cardiovascular medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Myung-Yong LeeDivision of Cardiology, Department of Internal Medicine, Dankook University, Chung Nam, South Korea.
Sola Han *Pharmaceutical Economics, Big Data Analysis & Policy, College of Pharmacy, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul, South Korea.
Oh Young BangDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Young Keun OnDepartment of Cardiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Sung-Won JangDivision of Cardiology, Department of Internal Medicine, Catholic University of Korea, Seoul, South Korea.
Seongwook HanDivision of Cardiology, Department of Internal Medicine, Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
Jaeyun RyuPfizer Korea Ltd, Seoul, South Korea.
Yoo-Jung ParkPfizer Korea Ltd, Seoul, South Korea.
Seongsik KangPfizer Korea Ltd, Seoul, South Korea.
Hae Sun Suh *Pharmaceutical Economics, Big Data Analysis & Policy, College of Pharmacy, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul, South Korea. haesun.suh@khu.ac.kr.ORCID http://orcid.org/0000-0003-3445-6607
Young-Hoon KimDivision of Cardiology, Department of Internal Medicine, College of Medicine, Korea University Medical Center, Korea University, 73 Inchon-ro, Seongbuk-gu, Seoul, South Korea. yhkmd@korea.ac.kr.
Kyung Hee University · KRPfizer (South Korea) · KRSamsung Medical Center · KRCatholic University of Korea · KRDankook University · KRKorea University Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTreatment persistence for anticoagulant therapy is important in preventing thromboembolism in nonvalvular atrial fibrillation (NVAF) patients. Understanding drug utilization pattern and treatment changes in oral anticoagulant (OAC) users may facilite better NVAF management. Thus, our study aimed to examine OAC treatment patterns preceding events leading to switch or discontinuation and medication adherence in Korean NVAF patients.

methodsWe conducted a drug utilization study on all Korean patients with atrial fibrillation (AF) newly prescribed OACs between July 2015 and November 2016 using the national claims data. We assessed treatment changes such as switching and discontinuation from index OAC and relevant events preceding the change and examined patient characteristics as predictors of changes that occurred among OAC users. Medication adherence was compared among OAC users by calculating the medication possession ratio (MPR).

resultsA total of 48,389 NVAF patients were identified who initiated OACs within the study period. Most initiated nonvitamin K antagonist oral anticoagulants (NOACs) (22% apixaban, 24% dabigatran, 37% rivaroxaban), and 18% initiated warfarin. The frequency of switch to another OAC was 8.8% for apixaban, 16.1% for dabigatran, 6.6% for rivaroxaban, and 19.1% for warfarin. The frequency of discontinuation was lower for apixaban (22.9%), dabigatran (26.3%), and rivaroxaban (25.7%) than warfarin (31.6%). Compared to warfarin, NOAC users were less likely to switch treatment. Thromboembolic event was the most common clinical event preceding switch from warfarin to NOAC and from NOAC to warfarin. Discontinuation of OAC was often preceded by a bleeding event. Patients who initiated apixaban showed significantly higher mean MPR compared to those on dabigatran and warfarin.

conclusionIn real-world practice in Korea, we have observed treatment change to be common in OAC users. Our results indicate better medication adherence with NOACs than with warfarin. (ClinicalTrials.gov registration number NCT03572972).

Indexed as

Atrial FibrillationStrokeAdministration, OralAnticoagulantsDabigatranDrug UtilizationHumansPyridonesRivaroxabanWarfarinAnticoagulantsDabigatranPyridonesRivaroxabanWarfarinAnticoagulantsAtrial fibrillationMedication adherenceStrokeTreatment pattern

Identifiers

PMID35524839
OpenAlexW4228999874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.